Impact of infectious comorbidity and overall time of hospitalization in total outpatient management of acute myeloid leukemia patients following venetoclax and hypomethylating agents. (28th February 2022)

• Record Type: Journal Article
• Authors: Papayannidis, Cristina; Nanni, Jacopo; Cristiano, Gianluca; Marconi, Giovanni; Sartor, Chiara; Parisi, Sarah; Zannoni, Letizia; Saed, Rashed; Ottaviani, Emanuela; Bandini, Lorenza; Testoni, Nicoletta; Baldazzi, Carmen; Solli, Vincenza; Ricci, Paolo; Di Giovanni Bezzi, Chiara; Abd‐alatif, Rania; Stanzani, Marta; Paolini, Stefania; Cavo, Michele; Curti, Antonio
• Is Part Of: European journal of haematology. Volume 108:Number 6(2022)
• Page Start: 449
• Page End: 459
• Publication Date: 2022-02-28
• Subjects: acute myeloid leukemia -- hospitalization -- hypomethylating agents -- infections -- outpatient -- real life -- Venetoclax; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; Blood -- Periodicals; 616.15005
• DOI: 10.1111/ejh.13753
• Languages: English
• ISSNs: 0902-4441

Abstract

Abstract: Venetoclax (VEN) and hypomethylating agent (HMAs) regimens are emerging as the standard of care for unfit for chemotherapy acute myeloid leukemia (AML) patients, but the safety and feasibility of a total outpatient management have not been fully investigated. Fifty‐nine AML patients with active disease received VEN and HMAs. Nineteen out of 59 (32.2%) patients received the first cycle as inpatients, whereas 40/59 (67.8%) patients were treated in the outpatient setting. No significant differences were observed with regard to incidence of adverse events (AEs), including tumor lysis syndrome (TLS), and the 30‐day and 60‐day mortality was comparable. Notably, an infectious prophylaxis inspired to that adopted during intensive chemotherapy resulted in a low infection rate with a reduced bacterial infections incidence in out‐ versus hospitalized patients ( p < .0001). The overall time of hospitalization was significantly shorter in patients who received a total outpatient treatment as compared to those who received the first cycle as inpatients (5.9 vs. 39.7 days, p < .0001). Despite the adopted differences in treatment management, the efficacy was similar. These data indicate that a total outpatient management of VEN and HMAs is feasible in AML patients without negatively impacting on treatment efficacy and may yield pharmacoeconomic and quality‐of‐life benefits.